<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254083</url>
  </required_header>
  <id_info>
    <org_study_id>1192.2</org_study_id>
    <nct_id>NCT02254083</nct_id>
  </id_info>
  <brief_title>Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects</brief_title>
  <official_title>Tolerability and Pharmacokinetics/-Dynamics of 0.5 mg and 1.0 mg (Actual 0.8 mg) of BIBT 986 BS Per Hour Given as IV Infusion Over 32 Hours in Healthy Male Subjects. Placebo Controlled, Double Blind Randomised at Each Dose Level</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess the tolerability of an intravenous infusion of 0.5 and 1.0 mg (actual 0.8 mg)
      BIBT 986 BS per hour over 32 hours as well as pharmacokinetics and the effect on blood
      coagulation parameters
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CT (concentration of the analyte at the end of drug infusion)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Css (steady state concentration of the analyte in plasma following a constant rate infusion)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (time from dosing to the maximum concentration of the analyte in plasma)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single dose administration)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 (Terminal half-life of the analyte in plasma after single dose administration)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tz (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration after single dose administration)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>λz (terminal rate constant of the analyte in plasma)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRTinf (mean residence time of the analyte in the body after intravenous infusion)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL (Total clearance of the analyte in plasma following intravascular administration)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vss (Apparent volume of distribution at steady state following intravascular administration)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz (apparent volume of distribution during the terminal phase λz following intravascular administration)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of parent drug eliminated in urine (Ae)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in activated partial thromboplastin time (aPTT)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in prothrombin time (PT)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ecarin clotting time (ECT)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in thrombin time (TT)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in vital signs</measure>
    <time_frame>up to 4 days</time_frame>
    <description>Pulse rate, systolic &amp; diastolic blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in International Normalised Ratio (INR)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction of administered drug excreted unchanged in urine (fe)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLR (renal clearance of the analyte in plasma following intravascular administration)</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIBT 986 BS - low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBT 986 BS - high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBT 986 BS - low</intervention_name>
    <arm_group_label>BIBT 986 BS - low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBT 986 BS - high</intervention_name>
    <arm_group_label>BIBT 986 BS - high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects as determined by results of screening

          -  Signed written informed consent in accordance with Good Clinical Practice (GCP) and
             local legislation

          -  Age &gt;= 18 and &lt;= 55 years

          -  BMI &gt;= 18.5 and &lt;= 29.9 kg/m2

        Exclusion Criteria:

          -  Any finding of the medical examination (including blood pressure, pulse rate, and
             electrocardiogram) deviating from normal and of clinical relevance

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic
             or hormonal disorders

          -  Surgery of gastrointestinal tract (except appendectomy)

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  Relevant history of orthostatic hypotension, fainting spells or blackouts

          -  Abnormal PT, TT, aPTT (must be within the normal range after no more than one repeated
             test), thrombocytes &lt; 150000/μl (two repeats of the first test)

          -  Evidence of hematuria either macroscopically detectable or microscopic on urinalysis
             (normal microscopic results after no more than one repeated test)

          -  Evidence of blood dyscrasia, hemorrhagic diathesis, severe thrombocytopenia,
             cerebrovascular hemorrhage, bleeding tendencies associated with active ulceration or
             overt bleeding of gastrointestinal, respiratory or genitourinary tract or any disease
             or condition with hemorrhagic tendencies (e.g. cerebral aneurysm, dissecting aorta,
             Central nervous system (CNS) trauma, retinopathy, nephrolithiasis)

          -  Recent or contemplated diagnostic or therapeutic procedures with potential for
             uncontrollable bleeding (e.g. spinal puncture, lumbar block anaesthesia, surgery of
             CNS or eye or surgery resulting in large open surfaces) within 14 days before or after
             drug administration of this clinical trial

          -  Occult blood in 1 of 3 subsequent faecal samples collected for the pre-study
             examination

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Intake of drugs with a long half-life (&gt; 24 hours) (&lt; 1 month prior to administration
             or during the trial)

          -  Use of any drugs, within 14 days prior to administration or during the trial

          -  Participation in another trial with an investigational drug (&lt; 2 months prior to
             administration or during trial)

          -  Smoker (&gt; 10 cigarettes or &gt;3 cigars or &gt;3 pipes/day)

          -  Alcohol abuse (&gt; 60 g/day)

          -  Drug abuse

          -  Blood donation or loss &gt; 400 mL, &lt; 1 month prior to administration or during the trial

          -  Excessive physical activities &lt; 5 days prior to administration of study drug or during
             trial

          -  Clinically relevant laboratory abnormalities

          -  Veins unsuited for i.v. puncture and administration of prolonged infusions on either
             arm (e.g. veins which are difficult to locate, access or puncture, veins with a
             tendency to rupture during or after puncture, etc.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>September 30, 2014</last_update_submitted>
  <last_update_submitted_qc>September 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

